No Data
No Data
Sino Biopharmaceutical (01177.HK): Positive results obtained in phase III study of anlotinib hydrochloride capsules combined with chemotherapy for first-line treatment of advanced soft tissue sarcoma.
Sino Biopharm (01177.HK) announced on July 16th that the phase III clinical trial (ALTN-III-04) of Anlotinib Hydrochloride Capsules, a Type 1 innovative drug independently developed by the group, combined with chemotherapy for first-line treatment of advanced unresectable or metastatic soft tissue sarcoma, has completed the planned interim analysis. The independent data monitoring committee (IDMC) determined that the main research endpoint (PFS) did not progress and reached the planned superior efficacy boundary value, and the secondary endpoint (OS) showed a trend of benefit. The group has communicated with the drug evaluation center of the China National Medical Products Administration.
Express News | Sino Biopharmaceutical - Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule
Sino Biopharmaceutical Myelofibrosis Drug Gets NMPA's Nod for Marketing
Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration accepted its new drug marketing application for its moderate and high-risk myelofibrosis treatment drug,
Zhitong Hong Kong stocks have long known | The Fed's confidence in meeting inflation standards has increased. TCL Electronics (01070) is happy
Fed Chairman Powell said that the second quarter economic data has given policymakers more confidence in achieving sustainable inflation to the 2% target.
Sino Biopharmaceutical's New Drug Shows Promise
Sino Biopharmaceutical has announced the successful completion of a pivotal clinical trial for its innovative drug Rovadicitinib Tablet, aimed at treating moderate to high-risk myelofibrosis, and the subsequent acceptance of its new drug application by China’s drug regulatory authority. The Rovadicitinib Tablet, a self-developed JAK/ROCK inhibitor, shows promise in inhibiting tumor activity and has also demonstrated efficacy in treating chronic graft-versus-host disease. The company is expanding clinical research to further establish the drug’s therapeutic potential.
Sino Biopharm's type 1 innovative drug Rovadicitinib (TQ05105) tablet has been accepted for new drug application.
Sino Biopharm announced that the key registration clinical trial of Type 1 Innovative Drug Rovadicitinib (TQ05105) developed by the group for the treatment of high-risk and intermediate-risk myelofibrosis (MF) has completed final analysis and achieved the main endpoint.
No Data